Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156157 | 0.98 | HSD11B1 (0.40) | HSD11B1RIPK1ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL13640405 | 0.96 | HSD11B1 (0.34) | HSD11B1RIPK1FFAR3MCL1 | |
| SCHEMBL2278073 | 0.91 | FFAR3 (0.40) | FFAR3 | |
| SCHEMBL15308424 | 0.89 | HSD11B1 (0.35) | HSD11B1RIPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16578138 | 0.89 | HSD11B1 (0.35) | HSD11B1RIPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1255925 | 0.82 | LMNA (0.30) | — | |
| SCHEMBL19641218 | 0.77 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL20640552 | 0.77 | — | — | |
| SCHEMBL21803196 | 0.77 | MEN1 (0.30) | — | |
| SCHEMBL17048673 | 0.77 | NPSR1 (0.31) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874466-B | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | PFIZER INC. (US) | 2026-05-26 | — | — | CN | disclosed |
| US-12312344-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240368144-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-116874466-A | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-112672791-B | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200095239-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
| EP-1697354-B1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2013-08-07 | — | — | EP | disclosed |
| US-7671212-B2 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1551818-B1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | HSD11B1 1749/4885RIPK1 2189/4885ALDH1A1 500/4885 |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | HSD11B1 1093/4885RIPK1 3291/4885ALDH1A1 1739/4885 |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | HSD11B1 1102/4885RIPK1 2320/4885ALDH1A1 348/4885 |
| US-20240368144-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | HSD11B1 1093/4885RIPK1 3291/4885ALDH1A1 1739/4885 |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | HSD11B1 1093/4885RIPK1 3291/4885ALDH1A1 1739/4885 |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | HSD11B1 815/4885RIPK1 2920/4885ALDH1A1 1929/4885 |
| US-20200095239-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | HSD11B1 1093/4885RIPK1 3291/4885ALDH1A1 1739/4885 |
| US-12312344-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | HSD11B1 1093/4885RIPK1 3291/4885ALDH1A1 1739/4885 |
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | HSD11B1 1093/4885RIPK1 3291/4885ALDH1A1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.